The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.